









Markets
/
Stocks
/
nasdaq-fate
/

Fate Therapeutics Inc

FATE

1.190USD

0.0000.00%

Close 01/30, 16:00（ET）Quotes delayed by 15 min

137.25MMarket Cap

LossP/E TTM



Fate Therapeutics Inc

1.190

0.0000.00%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Fate Therapeutics Inc

Currency: USD Updated: 2026-01-29

Key Insights

Fate Therapeutics Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 99 out of 393 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.94.In the medium term, the stock price is expected to trend down.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Fate Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

99 / 393

Overall Ranking

208 / 4540

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Fate Therapeutics Inc Highlights

StrengthsRisks

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

Growing

The company is in a growing phase, with the latest annual income totaling USD 13.63M.

Overvalued

The company’s latest PE is -0.90, at a high 3-year percentile range.

Held by PRFDX

Star Investor PRFDX holds 10.24K shares of this stock.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

4.944

Target Price

+277.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-29

The current financial score of Fate Therapeutics Inc is 5.40, ranking 371 out of 393 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.74M, representing a year-over-year decrease of 43.36%, while its net profit experienced a year-over-year decrease of 32.36%.

Score

Industry at a Glance

Previous score

5.40

Change



Financials

5.65

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.31

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.15

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Fate Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-01-29

The current valuation score of Fate Therapeutics Inc is 8.80, ranking 17 out of 393 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.90, which is -49.07% below the recent high of -0.46 and -466.54% above the recent low of -5.11.

Score

Industry at a Glance

Previous score

8.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 99/393

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-29

The current earnings forecast score of Fate Therapeutics Inc is 7.50, ranking 284 out of 393 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 8.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

4.944

Target Price

+277.44%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Fate Therapeutics Inc

FATE

Apple Inc

AAPL

Ge Vernova Inc

GEV

Tapestry Inc

TPR

FMC Corp

FMC

Avantor Inc

AVTR

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-29

The current price momentum score of Fate Therapeutics Inc is 6.58, ranking 227 out of 393 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.35 and the support level at 1.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.66

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.030

Buy

RSI(14)

54.680

Neutral

STOCH(KDJ)(9,3,3)

63.002

Sell

ATR(14)

0.086

High Vlolatility

CCI(14)

36.321

Neutral

Williams %R

43.333

Buy

TRIX(12,20)

0.708

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.230

Sell

MA10

1.192

Sell

MA20

1.115

Buy

MA50

1.078

Buy

MA100

1.151

Buy

MA200

1.158

Buy

Institutional Confidence

Currency: USD Updated: 2026-01-29

The current institutional shareholding score of Fate Therapeutics Inc is 10.00, ranking 1 out of 393 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 121.91%, representing a quarter-over-quarter decrease of 1.55%. The largest institutional shareholder is Catherine Wood, holding a total of 10.31M shares, representing 8.94% of shares outstanding, with 0.62% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Redmile Group, LLC

12.88M

+0.09%

ARK Investment Management LLC

Star Investors

10.31M

The Vanguard Group, Inc.

Star Investors

8.77M

-14.97%

BlackRock Institutional Trust Company, N.A.

8.61M

+2.69%

Wilshire Advisors LLC

8.49M

Johnson & Johnson Innovation-JJDC, Inc.

3.38M

Acadian Asset Management LLC

2.46M

-0.55%

Geode Capital Management, L.L.C.

2.43M

+7.03%

Vestal Point Capital, LP

2.52M

-0.03%

State Street Investment Management (US)

2.42M

+8.43%

Risk Assessment

Currency: USD Updated: 2026-01-29

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Fate Therapeutics Inc is 2.87, ranking 190 out of 393 in the Biotechnology & Medical Research industry. The company's beta value is 2.25. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.